CYTALUX™ for Gastrointestinal Cancers
This study is testing a drug called CYTALUX™ (pafolacianine) along with a special camera that uses near-infrared (NIR) light. The goal is to see if CYTALUX™ can help doctors find gastrointestinal cancers like stomach, esophageal, and appendiceal cancers more easily during surgery. You might be able to join if you are 18 or older and have a diagnosis or strong suspicion of these types of cancer. The study will look at how well CYTALUX™ works over 12 months. The study is currently unclear about its recruitment status and plans to enroll 15 participants.
- Study design
- This is an open-label study, meaning both you and your doctors will know you are receiving CYTALUX™. It aims to enroll 15 adult participants.
- What's involved
- You will receive an injection of CYTALUX™ (pafolacianine) 1 to 24 hours before your standard surgery. During surgery, tumors will be checked with near-infrared imaging.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will assess the feasibility of CYTALUX™ over 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Miguel Burch, MD · PRINCIPAL_INVESTIGATOR · Cedars-Sinai Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Feasibility of CYTALUX™ (pafolacianine) with near-infrared (NIR) fluorescent imaging12 months
Determine feasibility of using CYTALUX™ (pafolacianine) injection with near-infrared (NIR) fluorescent imaging for detecting any type adenocarcinoma (gastric, esophageal and appendiceal) in at least 70% of the patients.